The coronavirus vaccine developed by China’s Sinovac has demonstrated an efficacy rate of 78 per cent in late-stage trials in Brazil, delivering a boost to China’s efforts to burnish its medical technology abroad and catch up with western vaccine manufacturers.
manbetx3.0 科兴(Sinovac)研发的新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗在巴西的III期试验中被证明有效率达78%，提振了manbetx3.0 在国外磨炼其医疗技术、追赶西方疫苗制造商的努力。
您已阅读8%（359字），剩余92%（4165字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。